As of the latest Form 4 filed Jun 15, 2026.
What Corvus Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 16 most recent filings for CRVS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | 2026-06-11 | Moore David Scott Director | PPurchase | +21.7K | $11.53 | $250K | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | MILLER RICHARD A MD President and CEO | PPurchase | +1.93K | $12.01 | $23.2K | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | MILLER RICHARD A MD, President and CEO | PPurchase | +5.00K | $12.05 | $60.3K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A. Director | MExercise | +15.0K | $2.12 | $31.8K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $1.64 | $24.6K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $2.49 | $37.4K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $0.97 | $14.5K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $0.99 | $14.8K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $2.60 | $39.0K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $2.74 | $41.1K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $3.27 | $49.0K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $2.00 | $30.0K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $3.61 | $54.1K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $12.50 | $188K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +15.0K | $9.70 | $146K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-28 | Thompson Peter A., Director | MExercise | +30.0K | $15.00 | $450K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also CRVS’s full analysis or the market-wide insider trading feed. The tabs above jump to CRVS’s other SEC data.
Source: SEC Form 4 filings for CRVS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.